



PRESS RELEASE

For Immediate Release

Corgenix Medical Named as Finalist for Product Innovation Award

Boulder County IQ Award nomination recognizes company for AspirinWorks aspirin effect test

BOULDER, Colo. — Aug. 8, 2008 – Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has been honored in the *Boulder County Business Report* (BCBR) IQ (Innovation Quotient) Awards. Corgenix Medical was selected as one of 30 finalists for its AspirinWorks test that determines the effect of aspirin to prevent blood clots in apparently healthy individuals on low-dose aspirin therapy.

As a finalist, Corgenix Medical is recognized as one of Boulder County's most innovative medical device providers in the Medical & Health category. The 10 most-innovative companies will be announced live at BCBR's ninth annual IQ Awards for innovation on Thursday, Aug. 14, 2008.

"We're honored to be selected as a finalist in the IQ Awards, which recognize some of the most innovative companies in the Boulder Valley," said Douglass Simpson, Corgenix President and Chief Executive Officer. "The AspirinWorks product represents pioneering work in the field of platelet aggregation and heart disease. This new test has the potential to positively impact the lives of millions in the U.S. and around the world by determining if the aspirin they are taking to prevent heart attacks and stroke is doing its job."

The AspirinWorks test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and is now available nationwide through major medical reference laboratories. The simple urine test assesses the effect of aspirin on platelets through direct measurement of thromboxane production (aspirin's target). The higher the levels of thromboxane, the less impact the aspirin is having.

Research studies have shown that about 25 percent of individuals are resistant to the anti-clotting effects of aspirin. Clinical studies have revealed that patients who are resistant to the effect of aspirin are more than 3 times more likely to die from heart disease.

This year, BCBR received nearly 60 nominations from companies in the Boulder Valley and selected three finalists in each of 10 business categories.

"Innovation in the Boulder Valley is stronger and more exciting than it's ever been," said Christopher Wood, publisher of the *Boulder County Business Report*. "We are extremely pleased to once again honor the most-innovative products and services in Boulder and Broomfield

counties. Our judges spent many hours reviewing all the nominations, and we feel that they've come up with an incredible list of finalists.”

For more information on the *Boulder County Business Report's* IQ awards, go to www.IQawards.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Dan Snyders
Vice President and Public Relations Supervisor
Armada Medical Marketing
Phone: 303-623-1190 x 230
Fax: 303-623-1191
dan@armadamedical.com